NASDAQ:SYBX

Synlogic Q4 2024 Earnings Results & Report

Synlogic logo
$0.98 0.00 (0.00%)
As of 11/18/2026 11:03 AM Eastern

Synlogic beat analyst earnings expectations in its Q4 2024 results, released March 6, 2025. The company reported EPS of -$0.06 versus the -$0.10 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call
8:30 AM ET

Synlogic EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Synlogic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Synlogic Q4 2024 Earnings FAQ

Synlogic (NASDAQ:SYBX) reported earnings of -$0.06 per share for Q4 2024, beating the consensus estimate of -$0.10. The report was announced on Thursday, March 6, 2025.

Synlogic Earnings Headlines

Synlogic (SYBX) Set to Post Earnings on Wednesday
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Synlogic Challenges Nasdaq Delisting Notice
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX) is a biotechnology company that has focused on developing “synthetic biotics”—engineered bacteria designed to perform therapeutic functions in the body. Its approach uses synthetic biology to modify microbes so they can produce or consume specific substances, with the aim of treating disease.

The company’s research has centered on rare metabolic disorders, including phenylketonuria (PKU) and homocystinuria. Its investigational programs were designed to help break down compounds that build up in people with these conditions. Synlogic has not been known for marketed medicines; its work has been primarily in research and clinical development.

Founded in 2013 as a spinout from the Massachusetts Institute of Technology, Synlogic has been based in Cambridge, Massachusetts. Its programs and platform have been directed mainly toward the development of treatments for patients with metabolic diseases.

View Synlogic Profile